Evidence map›Paper›PMID 39365110›Full record

ArticleFuture oncology (London, England)2024

The epidemiology, treatments and outcomes of patients with hormone receptor positive, human epidermal growth factor receptor 2 negative, node-positive early breast cancer in Taiwan.

Chao-Hsiun Tang, Rachel Sarah Newson, Ching-Hung Lin, Bill Hoi-Fong Chan, Bruce Cm Wang, Shih-Pei Shen, Serena Yu-Ju Shao

Abstract read
In one paragraph

Article in Future oncology (London, England), 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Chao-Hsiun TangSchool of Health Care Administration, College of Management, Taipei Medical University, Taipei, Taiwan.
Rachel Sarah NewsonEli Lilly & Company, Sydney, Australia.
Ching-Hung LinDepartment of Medical Oncology, National Taiwan University Hospital, Cancer Center Branch, Taipei, Taiwan.
Bill Hoi-Fong ChanEli Lilly & Company (Taiwan), Inc., Taipei, Taiwan.
Bruce Cm WangElysia Group Ltd., Taipei, Taiwan.
Shih-Pei ShenSchool of Health Care Administration, College of Management, Taipei Medical University, Taipei, Taiwan.
Serena Yu-Ju ShaoEli Lilly & Company (Taiwan), Inc., Taipei, Taiwan.

Funding

Eli Lilly and Company
6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

Biomarkers, TumorBreast NeoplasmsLymphatic MetastasisAdministrative Claims, HealthcareAdultAgedAntineoplastic Agents, HormonalAntineoplastic Combined Chemotherapy ProtocolsBreastBreast Neoplasms, MaleCross-Sectional StudiesErb-b2 Receptor Tyrosine KinasesFemaleHumansIncidenceKaplan-Meier EstimateAntineoplastic Agents, HormonalBiomarkers, TumorERBB2 protein, humanErb-b2 Receptor Tyrosine KinasesReceptors, EstrogenReceptors, Progesteroneearly breast cancerhealth economicsHER2-high-riskHR+node-positive

Identifiers

PMID39365110
PMCPMC11572189

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.